FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316835016> ?p ?o ?g. }

• W2316835016 abstract "There are currently no proven safe and effective oral cancer prevention treatments. Overall, approximately 5% of oral leukoplakias progress to squamous cell carcinoma and are therefore considered an important precursor lesion for cancer prevention intervention. Nuclear receptor agonists are agents that can affect cell maturation pathways in the oral cavity and other sites. The hypothesis of this National Cancer Institute/Division of Cancer Prevention (NCI/DCP)-sponsored trial is that 6 months of 45 mg pioglitazone daily will shrink oral premalignant lesions and favorably modulate surrogate endpoint biomarkers of cancer prevention. The study agent, pioglitazone, is a PPARγ agonist shown to modulate critical cellular pathways. There is preclinical evidence suggesting the potential efficacy of PPARγ ligands in prevention of cancer. Moreover, in an earlier nonrandomized phase IIa study, response rates of over 70% were achieved in patients with oral leukoplakia after 3 months of treatment. In this current study, 100 participants with dysplastic oral premalignant lesions are being recruited and randomized to active drug or placebo for a period of 6 months. The primary endpoint is lesion size reduction or histologic improvement after 6 months of drug intervention. The secondary endpoints are the following biomarkers: PPARγ, cyclin D1, p21, TUNEL assay for apoptosis, Ki-67 for proliferation, transglutaminase, involucrin, 15-PGDH, LOH, and the change in plasma level of CRP. Plasma drug levels and cotinine levels are also measured. Accrual and evaluation is planned for 24 months. Due to the large size of this study and the relative rarity of these lesions, an international interconsortium study was designed to facilitate accrual. The lead DCP Consortia institutions, University of Wisconsin Carbone Cancer Center (UWCCC) and University of Texas MD Anderson Cancer Center (MDACC), and their nine participating organizations, Memorial Sloan-Kettering Cancer Center, Columbia University Medical Center, Weill Medical College of Cornell University, University of Maryland, University of Minnesota, University of Iowa, University of Alabama, Roswell Park Cancer Institute, and European Institute of Oncology (EIO) in Milan, Italy, make up the 11 sites for accrual for this study. During the process of protocol development, a streamlined centralized pathology review system was developed to improve consistency in histological diagnosis utilizing a web-based Aperio system. Additionally, to insure high-quality data an extensive Manual of Procedures (MOP) delineating all protocol activities is used by all sites. Centralized data entry utilizing Westat-developed Remote Data Capture database is used. The data analysis will include stratification by group (UWCCC vs. MDACC vs. EIO) and severe vs. mild dysplasia. Study drug and placebo are encapsulated by Fisher BioServices. The repository for banked biological specimen for future studies is held at the Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics (3P) lab at UWCCC. In conclusion a large oral cancer prevention inter-consortium study has been designed and implemented at 10 U.S. sites and one Italian site to evaluate the efficacy of pioglitazone treatment in oral premalignant lesions. This talk is also presented as Poster A73. Citation Information: Cancer Prev Res 2010;3(12 Suppl):PR-10." @default.
• W2316835016 created "2016-06-24" @default.
• W2316835016 creator A5016030632 @default.
• W2316835016 creator A5020366697 @default.
• W2316835016 creator A5060031638 @default.
• W2316835016 creator A5067074708 @default.
• W2316835016 creator A5069756775 @default.
• W2316835016 creator A5078173230 @default.
• W2316835016 creator A5088979830 @default.
• W2316835016 date "2010-12-01" @default.
• W2316835016 modified "2023-09-26" @default.
• W2316835016 title "Abstract PR-10: Randomized placebo controlled trial of pioglitazone for oral premalignant lesions: A cross-consortium collaborative study in progress" @default.
• W2316835016 doi "https://doi.org/10.1158/1940-6207.prev-10-pr-10" @default.
• W2316835016 hasPublicationYear "2010" @default.
• W2316835016 type Work @default.
• W2316835016 sameAs 2316835016 @default.
• W2316835016 citedByCount "0" @default.
• W2316835016 crossrefType "proceedings-article" @default.
• W2316835016 hasAuthorship W2316835016A5016030632 @default.
• W2316835016 hasAuthorship W2316835016A5020366697 @default.
• W2316835016 hasAuthorship W2316835016A5060031638 @default.
• W2316835016 hasAuthorship W2316835016A5067074708 @default.
• W2316835016 hasAuthorship W2316835016A5069756775 @default.
• W2316835016 hasAuthorship W2316835016A5078173230 @default.
• W2316835016 hasAuthorship W2316835016A5088979830 @default.
• W2316835016 hasConcept C121608353 @default.
• W2316835016 hasConcept C126322002 @default.
• W2316835016 hasConcept C134018914 @default.
• W2316835016 hasConcept C141341695 @default.
• W2316835016 hasConcept C142724271 @default.
• W2316835016 hasConcept C143998085 @default.
• W2316835016 hasConcept C2777180221 @default.
• W2316835016 hasConcept C2778384471 @default.
• W2316835016 hasConcept C2780234812 @default.
• W2316835016 hasConcept C555293320 @default.
• W2316835016 hasConcept C71924100 @default.
• W2316835016 hasConceptScore W2316835016C121608353 @default.
• W2316835016 hasConceptScore W2316835016C126322002 @default.
• W2316835016 hasConceptScore W2316835016C134018914 @default.
• W2316835016 hasConceptScore W2316835016C141341695 @default.
• W2316835016 hasConceptScore W2316835016C142724271 @default.
• W2316835016 hasConceptScore W2316835016C143998085 @default.
• W2316835016 hasConceptScore W2316835016C2777180221 @default.
• W2316835016 hasConceptScore W2316835016C2778384471 @default.
• W2316835016 hasConceptScore W2316835016C2780234812 @default.
• W2316835016 hasConceptScore W2316835016C555293320 @default.
• W2316835016 hasConceptScore W2316835016C71924100 @default.
• W2316835016 hasLocation W23168350161 @default.
• W2316835016 hasOpenAccess W2316835016 @default.
• W2316835016 hasPrimaryLocation W23168350161 @default.
• W2316835016 hasRelatedWork W1650055942 @default.
• W2316835016 hasRelatedWork W1994807747 @default.
• W2316835016 hasRelatedWork W1999629524 @default.
• W2316835016 hasRelatedWork W2030129038 @default.
• W2316835016 hasRelatedWork W2147834058 @default.
• W2316835016 hasRelatedWork W2162500971 @default.
• W2316835016 hasRelatedWork W2226695843 @default.
• W2316835016 hasRelatedWork W2281717253 @default.
• W2316835016 hasRelatedWork W2400272669 @default.
• W2316835016 hasRelatedWork W2749195784 @default.
• W2316835016 hasRelatedWork W2766758038 @default.
• W2316835016 hasRelatedWork W2767729055 @default.
• W2316835016 hasRelatedWork W2791556207 @default.
• W2316835016 hasRelatedWork W2794108628 @default.
• W2316835016 hasRelatedWork W2887712943 @default.
• W2316835016 hasRelatedWork W2901981972 @default.
• W2316835016 hasRelatedWork W3093302449 @default.
• W2316835016 hasRelatedWork W3096044474 @default.
• W2316835016 hasRelatedWork W3120460469 @default.
• W2316835016 hasRelatedWork W3177680150 @default.
• W2316835016 isParatext "false" @default.
• W2316835016 isRetracted "false" @default.
• W2316835016 magId "2316835016" @default.
• W2316835016 workType "article" @default.